Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 and Glasdegib in Previously Untreated AML With MDS Related Changes or Therapy-related AML
NCT04231851Phase 2Active, not recruiting
- Sponsor
- University of California, Irvine
- Start
- Feb 2020
- Primary completion
- Jun 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glasdegib and daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by University of California, Irvine. Primary endpoint: Event-Free Survival at 6 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
glasdegibdaunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04231851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231851.